Condition
Familial Combined Hyperlipidemia
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03110432Completed
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
NCT02130505Not ApplicableCompleted
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
NCT00465751Early Phase 1Completed
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
Showing all 3 trials